-

INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims Against 3D Systems Corporation

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against 3D Systems Corporation (“3D Systems” or the “Company”) (NYSE: DDD). The investigation focuses on the Company’s possible violations of federal securities laws.

On March 2, 2021, 3D Systems issued a press release notifying investors that it would delay the filing of its annual report on a Form 10-K. However, the Company reported unaudited fourth quarter and full year 2020 financial results. The Company stated that “the delay in filing is primarily related to the presentation of cash flows associated with the divestiture process for its Cimatron and GibbsCam software businesses.”

Following this news, 3D Systems’ stock price fell $7.62 per share, or approximately 19.64%, to close at $31.17 per share on March 2, 2021, thereby injuring investors.

If you purchased or otherwise acquired 3D Systems’ securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NYSE:DDD

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

UNCY INVESTOR REMINDER: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.Investors have until November 2, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after...

YSS INVESTOR REMINDER: York Space Systems Inc. Investors Have Until October 30, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your York Space Systems Inc. (“York” or the “Company”) (NYSE: YSS) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until October 30, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadli...

BBNX INVESTOR ALERT: Securities Class Action Filed Against Beta Bionics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities during the period of July 30, 2025 through February 24, 2026, inclusive (“the Class Period”). Investors are encouraged to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or i...
Back to Newsroom